Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:1
  • preuzimanja u poslednjih 30 dana:0

Sadržaj

članak: 4 od 21  
Back povratak na rezultate
2013, vol. 70, br. 1, str. 38-45
Efikasnost amifostina u zaštiti od akutnih kardiotoksičnih efekata doksorubicina kod pacova
aVojnomedicinska akademija, Centar za kliničku farmakologiju, Beograd + Univerzitet odbrane, Medicinski fakultet Vojnomedicinske akademije, Beograd
bUniverzitet odbrane, Medicinski fakultet Vojnomedicinske akademije, Beograd + Vojnomedicinska akademija, Institut za naučne informacije, Beograd
cUniverzitet odbrane, Medicinski fakultet Vojnomedicinske akademije, Beograd + Vojnomedicinska akademija, Nacionalni centar za kontrolu trovanja, Beograd
dUniverzitet odbrane, Medicinski fakultet Vojnomedicinske akademije, Beograd + Vojnomedicinska akademija, Institut za patologiju i sudsku medicinu, Beograd
eUniverzitet odbrane, Medicinski fakultet Vojnomedicinske akademije, Beograd + Vojnomedicinska akademija, Klinika za infektivne i tropske bolesti, Beograd
Ključne reči: amifostin; doksorubicin; srce; lekovi, toksičnost; ćelija, zaštita; pacovi, wistar
Sažetak
Uvod/Cilj. Amifostin (AMI) je citoprotektor širokog spektra koji može da spreči ispoljavanje toksičnih efekata radio- i hemioterapije bez smanjenja njihovog antitumorskog dejstva. Cilj ove studije bio je ispitivanje efikasnosti AMI u zaštiti od akutnih kardiotoksičnih efekata citostatika doksorubicina (DOX) kod mužjaka Wistar pacova. Metode. AMI (300 mg/kg ip) davan je 30 min pre DOX (6 mg/kg i 10 mg/kg iv). Ispitivanje toksičnih efekata DOX, kao i kardioprotektivne efikasnosti AMI sprovedeno je 48 sati nakon njihove primene. U tu svrhu određivana je serumska aktivnost enzima, koji su poznati kao markeri oštećenja miokarda (kreatin kinaze - CK, aspartat aminotransferaze - AST, laktat dehidrogenaze - LDH, i njenog izoenzima α-hidroksibutirat dehidrogenaze - α-HBDH), i izvršena je patohistološka i ultrastrukturna analiza tkiva miokarda. Rezultati. Amifostin je uspešno sprečio značajno povećanje aktivnosti enzima CK, AST, LDH i α-HBDH u serumu životinja kojima je dat DOX u dozi od 6 mg/kg (121,14 ± 18,37 vs 167,70 ± 44,24; 771,42 ± 161,99 vs 1057,00 ± 300,00; 3230,00 ± 1031,73 vs 4243,10 ± 904,06; 202,57 ± 42,46 vs 294,90 ± 80,20 UI/l, redom), dok je kod pacova koji su dobijali DOX u dozi od 10 mg/kg smanjio skor oštećenja miokada sa 2,62 ± 0,51 na 1,62 ± 0,51, odnosno na vrednost skora dobijenu u grupi pacova sa nižom dozom DOX (6 mg/kg). Ultrastrukturna analiza tkiva miokarda pokazala je da je prethodna primena AMI kod pacova koji su dobijali DOX u dozi od 6 mg/kg uspešno zaštitila sarkolemu kardiomiocita i smanjila oštećenje mitohondrija i kapilara, kao i pojavu apoptoze endotelnih ćelija. Sam AMI nije izazvao nikakve značajnije promene u ispitivanim parametrima u poređenju sa intaktnim (kontrolnim) pacovima. Zaključak. Amifostin ispoljava značajan kardioprotektivni efekat kod pacova u ranom periodu posle primene pojedina čnih visokih doza DOX. Ovaj nalaz ukazuje na potencijal AMI da bude uspešan kardioprotektor i kod onkoloških bolesnika koji primaju DOX.
Reference
Arola, O.J., Saraste, A., Pulkki, K., Kallajoki, M., Parvinen, M., Voipio-Pulkki, L.M. (2000) Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer research, 60(7): 1789-92
Berthiaume, J.M., Wallace, K.B. (2007) Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biology and Toxicology, 23(1): 15-25
Bhutia, Y.D., Vijayaraghavan, R., Pathak, U. (2010) Analgesic and anti-inflammatory activity of amifostine, DRDE-07, and their analogs, in mice. Indian journal of pharmacology, 42(1): 17-20
Bolaman, Z., Cicek, C., Kadikoylu, G., Barutca, S., Serter, M., Yenisey, C., Alper, G. (2005) The Protective Effects of Amifostine on Adriamycin-Induced Acute Cardiotoxicity in Rats. Tohoku Journal of Experimental Medicine, 207(4): 249-253
Bolman, Z., Akalin, N., Koseogly, M.H., Demir, S., Kadikoylu, G., Atalay, H., i dr. (2003) Effects of amifostine pre-treatment against adriamycininduced lipid peroxidation in rat heart. Haema, 6: 61-4
Buja, L.M., Vela, D. (2008) Cardiomyocyte death and renewal in the normal and diseased heart. Cardiovascular pathology, 17(6): 349-74
Capizzi, R.L. (1999) The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Seminars in oncology, 26(2 Suppl 7): 3-21
Chabner, B.A., Alegra, C.J., Curt, G.A., Calabresi, P. (2006) Chemotherapy of neoplastic diseases. u: Brunton L.L., Lazo J.S., Parker K.L. [ur.] Goodman & Gilman's the pharmacological basis of therapeutics, New York: McGraw Hill, p. 1315-404
Culy, C.R., Spencer, C.M. (2001) Amifostine: An update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs, 61(5): 641-84
Dobrić, S., Dragojević-Simić, V., Bokonjić, D., Milovanović, S., Marinčić, D., Jović, P. (1998) The efficacy of Selenium, WR-2721, and Their Combination in the Prevention of Adriamycin-Induced Cardiotoxicity in Rats. J Environment Pathol Toxicol Oncol, 17(3-4); 291-9
Doroshow, J.H. (1991) Doxorubicin-induced cardiac toxicity. N Engl J Med, 324(12): 843-5
Dragojevic-Simic, V.M., Dobric, S.L.J., Bokonjic, D.R., Vucinic, Z.M., Sinovec, S.M., Jacevic, V.M., Dogovic, N.P. (2004) Amifostine protection against doxorubicin cardiotoxicity in rats. Anti-cancer drugs, 15(2): 169-78
Dragojevic-Simic, V., Jacevic, V.M., Dobric, S.L., Djordjevic, A.N., Bokonjic, D.R., Bajcetic, M.P., Injac, R.M. (2011) Anti-inflammatory Activity of Fullerenol C-60(OH)(24) Nanoparticles in a Model of Acute Inflammation in Rats. Digest Journal of Nanomaterials and Biostructures, vol. 6, br. 2, str. 819-827
Dragojević-Simić, V., Dobrić, S., Kilibarda, V., Bokonjić, D., Milovanović, S. (1996) Cytoprotector amifostine (WR-2721): Pharmacokinetic properties and analytical methods for drug determination. Arch Toxicol Kinet Xenobiot Metab, 4: 185-197
Dragojević-Simić, V., Dobrić, S. (1996) The cytoprotective agent amifostine (WR-2721): Current clinical use and trends in its development. Vojnosanit Pregl, 53(4): 305-10
Fu, P., Birukova, A.A., Xing, J., Sammani, S., Murley, J.S., Garcia, J.G.N., Grdina, D.J., Birukov, K.G. (2009) Amifostine reduces lung vascular permeability via suppression of inflammatory signalling. European respiratory journal, 33(3): 612-24
Gille, L., Nohl, H. (1997) Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. Free radical biology & medicine, 23(5): 775-82
Grdina, D.J., Murley, J.S., Kataoka, Y. (2002) 22. Jahrestagung der Deutschen Gesellschaft für Senologie. Onkologie, 25(Suppl. 2): 2-39
Griser-Aleksić, N., Nikolić, V., Bogdanović, G., Baltić, V., Spasić, M. (1994) Prevencija kardiotoksičnosti doxorubicina selenom. Onkološki arhiv, 2(4): 195-197
Jensen, R.A. (1986) Doxorubicin cardiotoxicity: Contractile changes after long-term treatment in the rat. Journal of pharmacology and experimental therapeutics, 236(1): 197-203
Keizer, H.G., Pinedo, H.M., Schuurhuis, G.J., Joenje, H. (1990) Doxorubicin (adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacology & Therapeutics, 47(2): 219-231
Kotamraju, S., Konorev, E.A., Joseph, J., Kalyanaraman, B. (2000) Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. Journal of biological chemistry, 275(43): 33585-92
Kouvaris, J.R., Kouloulias, V.E., Vlahos, L.J. (2007) Amifostine: The first selective-target and broad-spectrum radioprotector. oncologist, 12(6): 738-47
L'Ecuyer, T., Allebban, Z., Thomas, R., Vander, H.R. (2004) Glutathione S-transferase overexpression protects against anthracycline-induced H9C2 cell death. American journal of physiology. Heart and circulatory physiology / Am. J. Physiol. Heart Circ. Physiol., 286(6): H2057-64
Maisch, B. (1999) How cardiac cells die: Necrosis, oncosis and apoptosis. Herz, 24(3): 181-8
Marzatico, F., Porta, C., Moroni, M., Bertorelli, L., Borasio, E., Finotti, N., Pansarasa, O., Castagna, L. (2000) In vitro antioxidant properties of amifostine (WR-2721, Ethyol). Cancer chemotherapy and pharmacology, 45(2): 172-6
Milic-Torres, V., Srdjenovic, B., Jacevic, V., Simic, V.D., Djordjevic, A., Simplício, A.L. (2010) Fullerenol C60(OH)24 prevents doxorubicin-induced acute cardiotoxicity in rats. Pharmacological reports, 62(4): 707-18
Murley, J.S., Kataoka, Y., Weydert, C.J., Oberley, L.W., Grdina, D.J. (2006) Delayed radioprotection by nuclear transcription factor kappaB -mediated induction of manganese superoxide dismutase in human microvascular endothelial cells after exposure to the free radical scavenger WR1065. Free radical biology & medicine, 40(6): 1004-16
Nazeyrollas, P., Prévost, A., Baccard, N., Manot, L., Devillier, P., Millart, H. (1999) Effects of amifostine on perfused isolated rat heart and on acute doxorubicin-induced cardiotoxicity. Cancer chemotherapy and pharmacology, 43(3): 227-32
Olson, H.M., Shannon, C.F. (1979) Alterations of lactate dehydrogenase isoenzymes with subacute adriamycin toxicity. Cancer treatment reports, 63(11-12): 2057-9
Olson, H.M., Capen, C.C. (1977) Subacute cardiotoxicity of adriamycin in the rat: Biochemical and ultrastructural investigations. Laboratory investigation; a journal of technical methods and pathology, 37(4): 386-94
Pai, V.B., Nahata, M.C. (2000) Cardiotoxicity of chemotherapeutic agents: Incidence, treatment and prevention. Drug safety, 22(4): 263-302
Papadopoulou, L.C., Theophilidis, G., Thomopoulos, G.N., Tsiftsoglou, A.S. (1999) Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: Suppression of cytochrome c oxidase II gene expression. Biochemical pharmacology, 57(5): 481-9
Pelikan, P.C., Weisfeldt, M.L., Jacobus, W.E., Miceli, M.V., Bulkley, B.H., Gerstenblith, G. (1986) Acute doxorubicin cardiotoxicity: Functional, metabolic, and morphologic alterations in the isolated, perfused rat heart. Journal of cardiovascular pharmacology, 8(5): 1058-66
Piper, J.R., Stringfellow, C.R., Elliott, R.D., Johnston, T.P. (1969) S-2-(omega-aminoalkylamino)ethyl dihydrogen phosphorothioates and related compounds as potential antiradiation agents. Journal of medicinal chemistry, 12(2): 236-43
Potemski, P., Polakowski, P., Wiktorowska-Owczarek, A.K., Owczarek, J., Płuzańska, A., Orszulak-Michalak, D. (2006) Amifostine improves hemodynamic parameters in doxorubicin-pretreated rabbits. Pharmacological reports, 58(6): 966-72
Simůnek, T., Stérba, M., Popelová, O., Adamcová, M., Hrdina, R., Gersl, V. (2009) Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacological reports, 61(1): 154-71
Singal, P.K., Iliskovic, N. (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med, 339(13): 900-5
Spencer, C.M., Goa, K.L. (1995) Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs, 50(6): 1001-31
Sweetman, S.C., ur. (2009) Martindale: The complete drug reference. London: Pharmaceutical Press
Tesoriere, L., Ciaccio, M., Valenza, M., Bongiorno, A., Maresi, E., Albiero, R., Livrea, M.A. (1994) Effect of vitamin A administration on resistance of rat heart against doxorubicin-induced cardiotoxicity and lethality. Journal of Pharmacology and Experimental Therapeutics, 269(1), 430-6
Trajković, S., Dobrić, S., Jaćević, V., Dragojević-Simić, V., Milovanović, Z., Dordević, A. (2007) Tissue-protective effects of fullerenol C60(OH)24 and amifostine in irradiated rats. Colloids and surfaces. B, Biointerfaces, 58(1): 39-43
Trump, B.F., Berezesky, I.K. (1998) Oncosis, apoptosis and necrosis: The role of [Ca2+]i deregulation. u: Electron Microscopy, 811-2, IV
Warren, M.C., Bump, E.A., Medeiros, D., Braunhut, S.J. (2000) Oxidative stress-induced apoptosis of endothelial cells. Free radical biology & medicine, 29(6): 537-47
Wouters, K.A., Kremer, L.C.M., Miller, T.L., Herman, E.H., Lipshultz, S.E. (2005) Protecting against anthracycline-induced myocardial damage: A review of the most promising strategies. British journal of haematology, 131(5): 561-78
Xiaoping, L., Evrovsky, Y., Cole, D., Trines, J., Benson, L.N., Lehotay, D.C. (1997) Doxorubicin-induced acute changes in cytotoxic aldehydes, antioxidant status and cardiac function in the rat. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1360(1): 45-52
Zhang, J., Clark, J.R., Herman, E.H., Ferrans, V.J. (1996) Doxorubicin-induced apoptosis in spontaneously hypertensive rats: Differential effects in heart, kidney and intestine, and inhibition by ICRF-187. Journal of molecular and cellular cardiology, 28(9): 1931-43
Zhang, Y., Shi, J., Li, Y., Wei, L. (2009) Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Archivum Immunologiae et Therapiae Experimentalis, 57(6): 435-445
 

O članku

jezik rada: engleski
vrsta rada: originalan članak
DOI: 10.2298/VSP110905041D
objavljen u SCIndeksu: 08.01.2013.
metod recenzije: dvostruko anoniman

Povezani članci

Srps arh celokup lekarstvo (2016)
Ugljenični nanomaterijali - biološki aktivni derivati fulerena
Bogdanović Gordana, i dr.

Arhiv za farmaciju (2005)
Racionalna primena terapijske supstitucije hormona i bisfosfonata
Pokrajac Milena

Arhiv za farmaciju (2007)
Farmakologija antidepresiva
Stepanović-Petrović Radica M.

prikaži sve [42]